PCNA and neoplasm: Quantification of PCNA-positive cells by field exhibited a regorafenib reduction of tumor proliferation (377 ± 140), compared to vehicle-treated animals (563 ± 62) that was potently increased by A-1331852 co-administration (70 ± 73).